Erik Mascher

Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase.

Part of General Electric Co., General Electric Healthcare España SA is a private company based in Alcobendas, Spain. The Spanish company specializes in providing innovative solutions to customers across different industries to accelerate the electrification and decarbonization of the world. The company's GE digital software is an essential tool that helps customers achieve their goals. Recently, the company has introduced six GE innovations that are about to change everything.

Karessa Pharma Holding AB engages in the development and commercialization of products in the therapeutic area of erectile dysfunction. Its patented drug is an alignate-based polymer film that is applied to the oral mucosa, which then rapidly delivered out into the bloodstream. The company was founded by Fredrik Hubinette on September 11, 2013 and is headquartered in Taby, Sweden.